1817698-21-7
1817698-21-7 结构式
基本信息
BDP5290
BDP-5290
BDP 5290
1H-Pyrazole-3-carboxamide, 4-chloro-1-(4-piperidinyl)-N-[3-(2-pyridinyl)-1H-pyrazol-4-yl]-
物理化学性质
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2025/05/22 | HY-12437 | BDP5290 | 1817698-21-7 | 1 mg | 654元 |
| 2025/05/22 | HY-12437 | BDP5290 | 1817698-21-7 | 10 mM * 1 mLin DMSO | 1227元 |
| 2025/05/22 | HY-12437 | BDP5290 BDP5290 | 1817698-21-7 | 5mg | 1500元 |
常见问题列表
|
ROCK1 5 nM (IC 50 ) |
ROCK2 50 nM (IC 50 ) |
MRCKα 10 nM (IC 50 ) |
MRCKβ 100 nM (IC 50 ) |
The K i of BDP5290 for MRCKα is 10 nM, which is slightly more than the K i of 4 nM for MRCKβ. 3 μM BDP5290 completely inhibits myosin II light chain (MLC) phosphorylation induced by MRCKβ, but not by ROCK1 or ROCK2. At higher concentrations, BDP5290 reduces MLC phosphorylation (pMLC) to undetectable levels. BDP5290 reduces MDA-MB-231 invasion at all tested concentrations starting from 0.1 μM, with virtually complete inhibition at 10 μM. After 24 hours in the presence of BDP5290 cell viability is slightly reduced with an EC 50 >10 μM. Wound closure is inhibited by >60% at 1 μM BDP5290, a concentration that has no effect on cell viability.